MR can be employed for PET attenuation correction, and PET/MR assessment for cardiac muscle viability delivered comparable results to PET acquired using PET/CT, according to research presented at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver.

At the 2013 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 8-12 in Vancouver, B.C., Canada, Siemens Healthcare (booth 720) will introduce Biograph mCT Flow – a groundbreaking new positron emission tomography/computed tomography (PET/CT) system that, for the first time ever, overcomes the limitations of conventional bed-based PET/CT with FlowMotion, a revolutionary new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

IBA Molecular North America, Inc. (IBA Molecular) and MIM Software Inc. (MIM Software™) have announced an agreement to co-develop enhancements to the IBA Molecular PETLinQ™ suite of products

PET/MR scans demonstrated a higher capacity for mapping recurrent prostate cancer by finding more areas of prostate cancer metastases than hybrid PET/CT imaging, according to the results of a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting in Vancouver.

Amyloid plaque burden has been linked with hypometabolism of neurons in areas of the brain associated with Alzheimer’s disease, according to the results of a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 annual meeting in Vancouver.

Ischemic small-vessel disease (SVD) wreaks havoc on the brain’s executive function and processing speed and is thought to be caused by gradual disconnects in the white matter tract and other cortical tissues leading to long-term cognitive impairment and disability. However, diffusion changes in apparently healthy tissues can reveal tell-tale signs of impending cognitive decline, according to a study published February 19 in the Annals of Neurology.

With a host of guidelines for tumor response presented by the now well known Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST), clinicians need to know that not all parameters are alike for predicting patient survival. Case in point, metabolic volume and lesion glycolysis using F-18 FDG PET has been found to be more predictive of survival in patients with metastatic colorectal tumors treated with radioembolization than standardized uptake guidelines, according to a study published May 31 in the Journal of Nuclear Medicine.

PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., will soon begin manufacturing Eli Lilly and Company’s AmyvidTM (Florbetapir (18F)) radiopharmaceutical in the United Kingdom, as well as in Spain and France, after signing a manufacturing services agreement with Eli Lilly and Company. Siemens’ PETNET Solutions will function as a contract manufacturer for Lilly after Lilly’s diagnostic radiopharmaceutical received marketing authorisation from the European Commission in early 2013.